A Study of Durvalumab in Patients With BR PDA Following Neoadjuvant Therapy and Successful Surgical Resection

Summary

This is a two-arm, open-label, phase II study of in adult patients who have successfully undergone R0/R1 resection of PDAs following neoadjuvant chemotherapy and completion of adjuvant chemotherapy. Within 1-3 months of treatment completion, patients will be enrolled and randomized at a 1:1 ratio to receive durvalumab versus observation.

Timeline

Start

2017-06-12

Primary completion

2019-04-01

Completion

2019-04-01

Outcome

Outcome not reported

Stopped: “Cancelled by PI”

Drugs

Indications